Go to the profile of HAOJUN LIAN
HAOJUN LIAN

BD, Innovent Biologics

TAHO is a specialty pharma focus on identifying, and developing new products that offer better therapeutic options to patient populations that may be under served. By utilizing company’s technology platform, it offers service niches in drug delivery. TAHO’s transdermal delivery platform allows the active ingredient to be absorbed by the skin and distributed through the bloodstream. It transform the patient care by: . Continuous delivery, safe, reliable, and pain-free application . Improved convenience, tolerability, and dosing . Flexible drug administration TAHO’s transmucosal delivery system, delivery the drug as a thin film, an evolution from tablets or capsules. It is a better patient care with: . Convenient dosing, no water needed . No risk of choking . Taste masking Let TAHO be your partner for innovative solutions and diverse your product pipeline
BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers. The Company is a world leader in understanding the central role of AXL kinase in promoting cancer spread, immune evasion and drug resistance – the cause of approximately 90 percent of cancer deaths. Inhibition of AXL kinase activity represents a novel approach to addressing a key mechanism in the evolution of cancer cell malignancy and aggressiveness, offering an opportunity to create new therapeutic options for cancer patients. BerGenBio’s lead product, BGB324, is a selective, potent and orally available small molecule AXL inhibitor. It is in Phase II clinical development, as a single agent and in combination with marketed immuno-oncology drugs, in three cancer indications with blockbuster potential: Acute myeloid leukaemia (AML); Advanced non-small-cell lung cancer (NSCLC); Triple negative breast cancer (TNBC) The Company is also developing a diversified pre-clinical pipeline of selective AXL inhibitors, including biologics and small molecules. BerGenBio intends to develop its drug candidates itself and through strategic partnerships in multiple indications, and retains all options for the future commercialization of its products.
Go to the profile of Carmen Ramirez
Carmen Ramirez

Sales Account Executive, Springer Nature

Founded in London (United Kingdom) in 2016, MicroQuin was born out of a collaborative and inclusive approach to research. MicroQuin is a biotechnology, R&D based company currently focusing on developing therapeutics to address a range of oncological disease. MicroQuin is progressing lead compounds into clinical trials, which offer a potential cure to Breast Cancer and other diseases.
Go to the profile of Albany A. Cordova Martins
Albany A. Cordova Martins

Business Development Executive, Nature Publishing Group, Springer Nature